A class of drugs known as nonsteroidal aromatase inhibitors, or NSAIs, is mainly prescribed to treat hormone-sensitive breast cancer. They function by preventing the enzyme aromatase from doing its job of turning androgens—hormones made by the ovaries and adrenal glands—into estrogen. Reducing the production of estrogen can aid in slowing or halting the spread of breast cancer because it can encourage the growth of some types of the illness.Letrozole is one of the NSAIs that is used often. Letrozole is an oral drug given once daily as part of adjuvant therapy or post-operative care, frequently for a number of years. It is also used to postmenopausal women whose breast cancer has advanced or returned after receiving tamoxifen therapy in the past. Letrozole can assist in preventing estrogen from promoting the growth of hormone receptor-positive breast cancer cells by lowering the body's oestrogen levels. Anastrozole is another NSAI that functions similarly to letrozole. Anastrozole is mainly prescribed to postmenopausal women who have hormone receptor-positive breast cancer and is also administered orally. In order to lower the chance of cancer returning following surgery, it is frequently recommended as adjuvant therapy.Another NSAI that differs slightly from letrozole and anastrozozole is called exemestane. Exemestane functions by irreversibly attaching to aromatase, thereby shutting it down, as opposed to blocking it. In postmenopausal women, this activity lowers estrogen levels, which helps to inhibit the formation of hormone receptor-positive breast cancer. Although NSAIs are usually well tolerated, they might have negative effects much like any other prescription. Hot flashes, joint pain, weariness, and osteoporosis are typical adverse effects. Postmenopausal women on NSAIs are frequently advised to take calcium and vitamin D supplements and undergo routine bone density tests because of the risk of bone loss.Letrozole, Anastrozole, and Exemestane are examples of nonsteroidal aromatase inhibitors that are crucial drugs for the treatment of hormone-sensitive breast cancer. They aid in slowing the growth and metastasis of cancer cells by preventing the synthesis or activity of estrogen. To guarantee the best possible treatment outcomes, individuals must, however, communicate with their healthcare providers about probable side effects and management techniques.